Skip to content
DraconiticResearch
Search Sources API
209,918 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY 4.0Cancers

Prostate Cancer Research in Ghana: A Scoping Review of Research Direction and Priorities

5 affiliations
  1. 1The Ghana integRative Approach to Cancer rEsearch (GRACE) Program, Korle Bu Teaching Hospital, Accra P.O. Box KB 369, Ghana
  2. 2Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana
  3. 3National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Accra P.O. Box KB 369, Ghana
  4. 4Department of Surgery, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana
  5. 5Department of Medicine, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana

Abstract

Background: In Ghana, prostate cancer (PCa) was the second most frequently diagnosed cancer among men in 2022, after liver cancer. Despite increasing research interest, evidence needed to guide PCa research priorities remains fragmented. This scoping review aimed to highlight research priorities and direction on PCa in Ghana by identifying thematic areas, gaps and potential areas for future research. Methods: The scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews checklist (PRISMA-ScR). A systematic search for relevant articles was conducted on four prominent databases: PubMed, Cochrane Library, Scopus, and ScienceDirect. Results: Data from eligible studies (n = 47) were synthesized across 15 thematic domains, including awareness, diagnosis and treatment approaches, genetics, dietary and metabolic factors, and pharmacological interventions. PCa awareness was high in some populations, but knowledge of specific disease features was variable, while screening uptake remained low. PSA was the most frequently assessed diagnostic marker, commonly evaluated alongside DRE and biopsy. Genomic studies identified potentially relevant genetic and molecular variants, although the evidence remains limited and requires further validation. Treatment patterns varied by disease stage and were also constrained by access- and resource-related factors. Epidemiological estimates differed by study design and population. Conclusions: PCa research in Ghana is broad but uneven, with significant gaps in early detection, population-level data, genomic validation and equitable access to care. Improving timely diagnosis and access to diagnostic and treatment services is important, while population-wide screening requires further evaluation of benefits, harms, cost-effectiveness, and health system capacity.

Related

  1. Special Issue: Prostate Cancer Research Update: Molecular Diagnostic Biomarkers
    Mikhail Baryshev
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
  2. PI PET for response assessment during antiangiogenic TKI therapy in radioiodine-refractory differentiated thyroid cancer: evidence and research priorities
    Cheng Niu, Hongdan Yao, Peiying Lin +2
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref
  3. D-DIMER AS A BIOMARKER IN PROSTATE CANCER: A SCOPING REVIEW OF CURRENT EVIDENCE
    Lívia Ferreira de SOUSA, Érica De Cássia SILVA, Bruno GIORNO +3
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textOncologyDOAJ
  4. Using secure WhatsApp-based digital recruitment as an intervention in prostate cancer research with black men
    Kai Wakeham, George Theodorakopoulos, Shancang Li +5
    Frontiers in Digital HealthPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  5. Resource Overlap and Reporting of Independence in Public Prostate Cancer Research
    W. Yue, A. K. Tewari, B. J. Padanilam
    medRxivPreprintCC BY-NC-NDFull textEpidemiology & public healthmedRxiv
BibTeX
@article{amoah2026prostate,
  title = {{Prostate Cancer Research in Ghana: A Scoping Review of Research Direction and Priorities}},
  author = {Isaac Amoah and Hannah Ayettey Anie and Daniel Tetteh and Vanessa Adu Sarpong and Kwaku Addai Arhin Appiah and Phyllis Tawiah},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18203246},
  url = {https://www.mdpi.com/2072-6694/18/20/3246},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Prostate Cancer Research in Ghana: A Scoping Review of Research Direction and Priorities
AU  - Isaac Amoah
AU  - Hannah Ayettey Anie
AU  - Daniel Tetteh
AU  - Vanessa Adu Sarpong
AU  - Kwaku Addai Arhin Appiah
AU  - Phyllis Tawiah
PY  - 2026
DA  - 2026/10/01
JO  - Cancers
DO  - 10.3390/cancers18203246
UR  - https://www.mdpi.com/2072-6694/18/20/3246
AB  - Background: In Ghana, prostate cancer (PCa) was the second most frequently diagnosed cancer among men in 2022, after liver cancer. Despite increasing research interest, evidence needed to guide PCa research priorities remains fragmented. This scoping review aimed to highlight research priorities and direction on PCa in Ghana by identifying thematic areas, gaps and potential areas for future research. Methods: The scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews checklist (PRISMA-ScR). A systematic search for relevant articles was conducted on four prominent databases: PubMed, Cochrane Library, Scopus, and ScienceDirect. Results: Data from eligible studies (n = 47) were synthesized across 15 thematic domains, including awareness, diagnosis and treatment approaches, genetics, dietary and metabolic factors, and pharmacological interventions. PCa awareness was high in some populations, but knowledge of specific disease features was variable, while screening uptake remained low. PSA was the most frequently assessed diagnostic marker, commonly evaluated alongside DRE and biopsy. Genomic studies identified potentially relevant genetic and molecular variants, although the evidence remains limited and requires further validation. Treatment patterns varied by disease stage and were also constrained by access- and resource-related factors. Epidemiological estimates differed by study design and population. Conclusions: PCa research in Ghana is broad but uneven, with significant gaps in early detection, population-level data, genomic validation and equitable access to care. Improving timely diagnosis and access to diagnostic and treatment services is important, while population-wide screening requires further evaluation of benefits, harms, cost-effectiveness, and health system capacity.
SN  - 2072-6694
ER  -